Amgen Tops Estimates Despite Mixed Performance of Key Drugs

Amgen Inc. reported better-than-expected first-quarter results even as some newer drugs that analysts expect to drive growth over the next few years underperformed.

While total revenue came in higher than Wall Street estimates, closely watched products such as the respiratory treatment Tezspire and Evenity for osteoporosis fell short of analyst projections.